MCID: MCS004
MIFTS: 46

Mucosal Melanoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Mucosal Melanoma

MalaCards integrated aliases for Mucosal Melanoma:

Name: Mucosal Melanoma 12 29 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050929
UMLS 70 C3898222

Summaries for Mucosal Melanoma

Disease Ontology : 12 A melanoma that has material basis in melanocytes located in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract.

MalaCards based summary : Mucosal Melanoma is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and malignant skin fibrous histiocytoma. An important gene associated with Mucosal Melanoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cisplatin and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include mucosal membranes lining the respiratory, skin and lymph node, and related phenotypes are behavior/neurological and hematopoietic system

Wikipedia : 73 Mucosal melanoma is a rare condition characterized by a melanoma of the mucous membranes. This subtype... more...

Related Diseases for Mucosal Melanoma

Diseases related to Mucosal Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 30.5 MITF IL2 CD274
2 malignant skin fibrous histiocytoma 30.2 NRAS KIT IFNA2 GNAQ GNA11
3 malignant conjunctival melanoma 30.1 NRAS IFNA2 GNAQ GNA11
4 vulvar melanoma 30.1 NRAS NF1 KIT GNAQ GNA11
5 acral lentiginous melanoma 30.0 TERT NRAS KIT CDKN2A CD274 BRAF
6 mucositis 29.9 VEGFA IL2 IFNA1
7 li-fraumeni syndrome 29.7 TP53 TERT NF1 CDKN2A
8 merkel cell carcinoma 29.7 TP53 KIT CDKN2A CD274
9 dermatofibrosarcoma protuberans 29.7 TP53 KIT CDKN2A
10 exanthem 29.7 VEGFA KIT IL2 IFNA1 CD274
11 neutropenia 29.6 TP53 IL2 IFNA2 IFNA1
12 malignant anus melanoma 29.4 NRAS MAGEC2 MAGEC1 KIT IL2 GNA11
13 thrombocytopenia 29.3 TERT KIT IL2 IFNA2 IFNA1 CD274
14 squamous cell carcinoma 29.3 VEGFA TP53 CTAG1B CDKN2A BRAF
15 nodular malignant melanoma 29.1 TP53 NRAS MITF KIT GNAQ GNA11
16 rhabdomyosarcoma 28.9 VEGFA TP53 NRAS NF1 KIT CDKN2A
17 gastrointestinal stromal tumor 28.9 VEGFA TP53 NF1 KIT CDKN2A BRAF
18 neuroblastoma 28.6 VEGFA TP53 TERT NRAS NF1 KIT
19 kidney cancer 28.5 VEGFA TP53 IL2 IFNA2 IFNA1 CDKN2A
20 ocular melanoma 28.3 VEGFA TERT NRAS KIT IL2 GNAQ
21 melanoma 28.2 VEGFA TP53 TERT NRAS MITF MAGEC2
22 melanoma, cutaneous malignant 1 27.8 TP53 TERT NRAS NF1 MITF KIT
23 skin melanoma 27.7 VEGFA TP53 TERT NRAS NF1 MITF
24 melanoma, uveal 27.5 VEGFA TP53 TERT NRAS NF1 MITF
25 skin carcinoma 27.2 VEGFA TP53 TERT NRAS NF1 MITF
26 melanomatosis 10.5 NRAS GNAQ
27 phakomatosis cesioflammea 10.4 GNAQ GNA11
28 rare tumor 10.4
29 meningeal melanocytoma 10.4 GNAQ GNA11
30 conjunctival nevus 10.4 NRAS GNAQ
31 urachal adenocarcinoma 10.4 NF1 BRAF
32 acneiform dermatitis 10.4 NRAS BRAF
33 cervical adenoid cystic carcinoma 10.4 KIT CDKN2A
34 meningeal melanoma 10.4 NRAS GNAQ GNA11
35 meningeal melanomatosis 10.4 NRAS GNAQ GNA11
36 malignant leptomeningeal tumor 10.4 NRAS GNAQ GNA11
37 central nervous system melanocytic neoplasm 10.4 NRAS GNAQ GNA11
38 hypomelanosis of ito 10.3 NRAS GNAQ GNA11
39 epstein-barr virus-associated gastric carcinoma 10.3 CDKN2A CD274
40 laryngeal small cell carcinoma 10.3 KIT CDKN2A
41 primary cutaneous diffuse large b-cell lymphoma, leg type 10.3 CDKN2A CD274
42 maxillary sinus benign neoplasm 10.3 KIT CDKN2A
43 childhood acute myeloid leukemia 10.3 NRAS KIT IL2
44 plexiform schwannoma 10.3 NF1 KIT
45 myelodysplastic/myeloproliferative neoplasm 10.3 NRAS NF1 KIT
46 small intestine leiomyoma 10.3 NF1 KIT
47 gallbladder melanoma 10.3 MITF IL2
48 spermatocytoma 10.3 MAGEC1 KIT CTAG1B
49 corneal intraepithelial neoplasm 10.3 IFNA2 IFNA1
50 sturge-weber syndrome 10.3 NF1 GNAQ GNA11

Graphical network of the top 20 diseases related to Mucosal Melanoma:



Diseases related to Mucosal Melanoma

Symptoms & Phenotypes for Mucosal Melanoma

MGI Mouse Phenotypes related to Mucosal Melanoma:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 BRAF CD274 CDKN2A GNA11 GNAQ IL2
2 hematopoietic system MP:0005397 10.44 BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
3 growth/size/body region MP:0005378 10.43 BAP1 BRAF CDKN2A GNA11 GNAQ IL2
4 immune system MP:0005387 10.42 BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
5 cellular MP:0005384 10.4 BAP1 BRAF CD274 CDKN2A IL2 KIT
6 endocrine/exocrine gland MP:0005379 10.4 BAP1 BRAF CDKN2A GNA11 GNAQ IL2
7 homeostasis/metabolism MP:0005376 10.4 BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
8 cardiovascular system MP:0005385 10.36 BAP1 BRAF CDKN2A GNA11 GNAQ IL2
9 mortality/aging MP:0010768 10.34 BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
10 craniofacial MP:0005382 10.31 BRAF GNA11 GNAQ KIT MITF NF1
11 integument MP:0010771 10.31 BAP1 BRAF CD274 CDKN2A GNA11 GNAQ
12 digestive/alimentary MP:0005381 10.3 BAP1 BRAF CDKN2A IL2 KIT NF1
13 embryo MP:0005380 10.25 BAP1 BRAF CDKN2A KIT MITF NF1
14 liver/biliary system MP:0005370 10.25 BRAF CDKN2A GNA11 IL2 KIT MITF
15 limbs/digits/tail MP:0005371 10.22 BRAF GNA11 GNAQ KIT MITF NF1
16 neoplasm MP:0002006 10.16 BAP1 BRAF CDKN2A IL2 KIT NF1
17 muscle MP:0005369 10.13 BAP1 BRAF CDKN2A GNA11 GNAQ KIT
18 hearing/vestibular/ear MP:0005377 10.12 BRAF GNA11 GNAQ KIT MITF NF1
19 normal MP:0002873 10.1 BRAF GNA11 GNAQ KIT MITF NF1
20 no phenotypic analysis MP:0003012 10.09 BAP1 CD274 CDKN2A IL2 KIT MITF
21 pigmentation MP:0001186 10.02 BRAF CDKN2A GNA11 GNAQ KIT MITF
22 reproductive system MP:0005389 9.96 BAP1 BRAF CDKN2A IL2 KIT MITF
23 respiratory system MP:0005388 9.93 BAP1 BRAF CDKN2A GNA11 GNAQ IL2
24 renal/urinary system MP:0005367 9.92 BRAF GNA11 GNAQ KIT MITF NF1
25 skeleton MP:0005390 9.73 BRAF CD274 CDKN2A GNA11 GNAQ KIT
26 vision/eye MP:0005391 9.28 BRAF CDKN2A IL2 KIT MITF NF1

Drugs & Therapeutics for Mucosal Melanoma

Drugs for Mucosal Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
3
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166 2942
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
7
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
8 interferons Phase 3
9 Interferon-alpha Phase 3
10 Interferon alpha-2 Phase 3
11 Alkylating Agents Phase 3
12 polysaccharide-K Phase 3
13 Tubulin Modulators Phase 3
14 Antimitotic Agents Phase 3
15 Albumin-Bound Paclitaxel Phase 3
16
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
17
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
18
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
19
Bevacizumab Approved, Investigational Phase 2 216974-75-3
20
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
21
Ceritinib Approved Phase 2 1032900-25-6
22
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
23
Trametinib Approved Phase 2 871700-17-3 11707110
24
Pembrolizumab Approved Phase 2 1374853-91-4
25
Lenvatinib Approved, Investigational Phase 2 417716-92-8
26
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
27
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
28
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
29
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
30
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
31 Vaccines Phase 2
32 Imatinib Mesylate Phase 2 220127-57-1 123596
33 Pharmaceutical Solutions Phase 2
34
Apatinib Phase 2 811803-05-1
35 Immunoglobulins, Intravenous Phase 2
36 Endostar protein Phase 2
37 Muromonab-CD3 Phase 1, Phase 2
38 Angiogenesis Inhibitors Phase 2
39 Antiviral Agents Phase 2
40 Protein Kinase Inhibitors Phase 2
41 Antibiotics, Antitubercular Phase 2
42 Immunosuppressive Agents Phase 2
43 Anti-Bacterial Agents Phase 2
44 Anti-Infective Agents Phase 2
45 Immunologic Factors Phase 2
46 Antifungal Agents Phase 2

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Randomized, Controlled, Phase III Trial Comparing High-Dose IFN-a2b With Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Unknown status NCT03435302 Phase 3 Temozolomide Plus Cisplatin;High-Dose IFN-a2b
2 A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
3 A Prospective Phase II Study in Patients With Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era Unknown status NCT03138642 Phase 2
4 A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma Unknown status NCT02023710 Phase 2 Paclitaxel;Carboplatin;Bevacizumab
5 A Phase II Trial of Dasatinib in KIT-Positive Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas Completed NCT00700882 Phase 2 dasatinib
6 A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin. Completed NCT00424515 Phase 2 Imatinib
7 A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma Completed NCT01961115 Phase 2 Epacadostat
8 A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma Completed NCT01395121 Phase 2 nilotinib
9 Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN) Recruiting NCT03235245 Phase 2 Nivolumab + Ipilimumab;Encorafenib + Binimetinib
10 A Randomized, Controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Axitinib in the First-Line Treatment of Patients With Advanced Mucosal Melanoma Recruiting NCT03941795 Phase 2 Axitinib 1 MG [Inlyta]
11 Phase II Clinical Study of CM082 Combined With JS001 in the Treatment of Advanced Mucosal Melanoma. Recruiting NCT03602547 Phase 2 CM082 plus JS001
12 Clinical Study of SHR-1210 Plus Apatinib in Patients With Advanced Mucosal Melanoma Whose Diseases Progress After Chemotherapy Recruiting NCT03986515 Phase 2 apatinib plus SHR-1210
13 Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252 Recruiting NCT03241186 Phase 2 Ipilimumab;Nivolumab;Nivolumab
14 A Multicenter, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab(JS001) After Chemotherapy in Combination With Endostar in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma Recruiting NCT04472806 Phase 2 Toripalimab;chemotherapy in combination with Endostar
15 A Monocentric, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Localized Mucosal Melanoma Recruiting NCT04180995 Phase 2 TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)
16 Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma Recruiting NCT04318717 Phase 1, Phase 2 Pembrolizumab
17 Phase II Multicentric Study: Efficacy Evaluation of Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy on Disease-free-survival (DFS) in Patients With Resectable Head and Neck Mucosal Melanoma Recruiting NCT03313206 Phase 2 Pembrolizumab
18 A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma Active, not recruiting NCT02535078 Phase 1, Phase 2 IMCgp100;durvalumab;tremelimumab
19 A Phase II Randomized, Control, Multi-center Study of Recombinant Humanized Anti-PD-1 mAb for Injection Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery Active, not recruiting NCT03178123 Phase 2
20 Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma Active, not recruiting NCT04091217 Phase 2 Atezolizumab;Bevacizumab
21 A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma Active, not recruiting NCT02071940 Phase 2 PLX3397
22 A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Combined With Temozolomide and Cisplatin in the Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Enrolling by invitation NCT04462965 Phase 2
23 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 2 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care;CDK4/6 and MEK inhibitor
24 A Phase II Study of Neoadjuvant Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma Not yet recruiting NCT04622566 Phase 2 Lenvatinib, Pembrolizumab
25 A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6 Not yet recruiting NCT04830124 Phase 2 Nemvaleukin Alfa Subcutaneous;Nemvaleukin Alfa Intravenous
26 Phase II Trial of mTOR Inhibitor Temsirolimus Combined With MEK Inhibitor AZD 6244 in Patients With BRAF Mutant Stage IV Melanoma Terminated NCT01166126 Phase 2 temsirolimus;selumetinib
27 Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma. Withdrawn NCT03758729 Phase 2 Nivolumab
28 A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn NCT03220009 Phase 2
29 A Dose Ranging Trial of Adenovirus CCL-21 Transduced MART-1/gp100 Peptide-Pulsed Dendritic Cells Matured Using Cytokines for Patients With Chemotherapy-Resistant Metastatic Melanoma Completed NCT00798629 Phase 1
30 Molecular Characterization of Primary Mucosal Melanoma Active, not recruiting NCT03319693

Search NIH Clinical Center for Mucosal Melanoma

Genetic Tests for Mucosal Melanoma

Genetic tests related to Mucosal Melanoma:

# Genetic test Affiliating Genes
1 Mucosal Melanoma 29

Anatomical Context for Mucosal Melanoma

The Foundational Model of Anatomy Ontology organs/tissues related to Mucosal Melanoma:

19
Mucosal Membranes Lining The Respiratory

MalaCards organs/tissues related to Mucosal Melanoma:

40
Skin, Lymph Node, Tongue, Brain, Tonsil, Eye, Small Intestine

Publications for Mucosal Melanoma

Articles related to Mucosal Melanoma:

(show top 50) (show all 826)
# Title Authors PMID Year
1
Recurrence of mucosal melanoma in Li-Fraumeni syndrome: A follow-up of an index case. 61
33732843 2021
2
The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. 61
33686688 2021
3
CDK4 and TERT amplification in head and neck mucosal melanoma. 61
33797827 2021
4
Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma. 61
33783056 2021
5
Mucosal Melanoma of the Hard Palate: Surgical Treatment and Reconstruction. 61
33804881 2021
6
Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma. 61
33707307 2021
7
BRAFV600E mutation in oral melanocytic nevus and oral mucosal melanoma. 61
33189579 2021
8
Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma. 61
33492992 2021
9
Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. 61
33724703 2021
10
Observed progression from melanosis with melanocyte hyperplasia to sinonasal melanoma with distant metastasis and a unique genetic rearrangement. 61
33694261 2021
11
Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. 61
33444116 2021
12
Characterization of Primary Cultures of Normal and Neoplastic Canine Melanocytes. 61
33802040 2021
13
Primary sinonasal malignant melanoma with systemic metastasis in a non-gray horse. 61
33292086 2021
14
Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004 to 2016: striking differences and similarities of two neighbouring countries. 61
33656221 2021
15
Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma. 61
33338202 2021
16
Primary BRAF Mutant Melanoma of the Lung Treated with Immunotherapy and Pulmonary Bilobectomy: A Case Report. 61
33731665 2021
17
Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients. 61
33648909 2021
18
Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases. 61
33503528 2021
19
Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. 61
33795130 2021
20
Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-Kit. 61
33741716 2021
21
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). 61
33234846 2021
22
Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. 61
33399091 2021
23
Identification of vital genes and pathways associated with mucosal melanoma in Chinese. 61
33189033 2021
24
Prognostic significance of regression and mitotic rate in head and neck cutaneous melanoma. 61
33614938 2021
25
Regional disease control in sinonasal mucosal melanoma: Systematic review and meta-analysis. 61
33151611 2021
26
Do Not Skip the Retroflexion: A Case of Disseminated Anorectal Mucosal Melanoma. 61
33553463 2021
27
Survival and Prognostic Nomogram for Primary Gastrointestinal Melanoma (PGIM): A Population-based Study. 61
33517303 2021
28
Regional lymph node infiltration and thick lesions are associated with poor prognosis in high-risk resected melanomas: A retrospective cohort study. 61
33456772 2021
29
Are our patients doing better? A single institution experience of an evolving management paradigm for sinonasal mucosal melanoma. 61
32958401 2021
30
Review of Dermoscopy and Reflectance Confocal Microscopy Features of the Mucosal Melanoma. 61
33429900 2021
31
The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: Systematic review and meta-analysis. 61
32926490 2021
32
Malignant melanoma of urethra in a young female - Case report and Literature review. 61
33716219 2021
33
A Rare Case of Oral Mucosal Amelanotic Melanoma in a 77-year-old Immunocompromised Man. 61
33584964 2021
34
Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study. 61
33747946 2021
35
Ultraviolet radiation drives mutations in a subset of mucosal melanomas. 61
33431815 2021
36
Malignant tumors of the hard palate: Report of 4 cases and review of the literature. 61
33360635 2021
37
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. 61
33483342 2021
38
An Overview of Liver Directed Locoregional Therapies. 61
33220800 2021
39
NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications. 61
32656925 2020
40
The molecular profile of mucosal melanoma. 61
33156594 2020
41
Variable Expression of S100 Protein in Sinonasal Malignant Mucosal Melanoma: A Potential Diagnostic Pitfall. 61
32239440 2020
42
Oral mucosal melanoma: Case report. 61
33505631 2020
43
Long interspersed nucleotide element-1 hypomethylation in canine malignant mucosal melanoma. 61
32187810 2020
44
Response to PD-1 blockade in a patient with mucosal melanoma of the middle ear: Case report. 61
33363953 2020
45
Dermatoscopy of melanoma according to type, anatomic site and stage: a 2020 update. 61
33314891 2020
46
Systemic Therapy for Melanoma: ASCO Guideline. 61
32228358 2020
47
Survival of oral mucosal melanoma according to treatment, tumour resection margin, and metastases. 61
32586691 2020
48
Primary tumor volume as a predictor of distant metastases and survival in patients with sinonasal mucosal melanoma. 61
32737953 2020
49
Development of Merkel Cell Carcinoma and Squamous Cell Carcinoma During Treatment With Pembrolizumab for Metastatic Mucosal Melanoma. 61
31584527 2020
50
Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. 61
32917657 2020

Variations for Mucosal Melanoma

Expression for Mucosal Melanoma

Search GEO for disease gene expression data for Mucosal Melanoma.

Pathways for Mucosal Melanoma

Pathways related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 VEGFA TP53 SPRED1 NRAS NF1 KIT
2
Show member pathways
13.8 VEGFA TP53 NRAS NF1 KIT IL2
3
Show member pathways
13.48 VEGFA TP53 NRAS KIT IL2 IFNA2
4
Show member pathways
13.25 VEGFA TP53 NRAS IL2 IFNA2 IFNA1
5
Show member pathways
13.07 TP53 NRAS IL2 IFNA2 IFNA1 GNAQ
6
Show member pathways
13.03 TP53 NRAS KIT IL2 GNA11 BRAF
7
Show member pathways
12.96 VEGFA TP53 SPRED1 NRAS NF1 KIT
8
Show member pathways
12.82 VEGFA TP53 NRAS KIT CDKN2A BRAF
9
Show member pathways
12.8 NRAS KIT GNAQ GNA11 BRAF
10
Show member pathways
12.77 NRAS MITF KIT GNAQ GNA11 CDKN2A
11
Show member pathways
12.76 VEGFA TP53 TERT NRAS KIT IL2
12 12.7 VEGFA TP53 NRAS NF1 KIT BRAF
13
Show member pathways
12.69 TP53 TERT NRAS KIT CDKN2A BRAF
14
Show member pathways
12.66 VEGFA TP53 NRAS IFNA2 IFNA1 GNAQ
15
Show member pathways
12.65 VEGFA NRAS NF1 KIT GNAQ BRAF
16
Show member pathways
12.58 VEGFA TP53 NRAS NF1 BRAF
17
Show member pathways
12.57 TP53 NRAS NF1 MITF CDKN2A BRAF
18
Show member pathways
12.46 NRAS IL2 IFNA2 IFNA1 BRAF
19 12.27 VEGFA TP53 NRAS BRAF
20
Show member pathways
12.27 VEGFA TP53 NRAS BRAF
21 12.25 TP53 TERT NRAS IL2 CDKN2A
22 12.16 VEGFA TP53 TERT NRAS MITF KIT
23
Show member pathways
12.12 TP53 TERT KIT IL2 IFNA2 IFNA1
24 12.11 VEGFA TP53 NF1 BRAF
25
Show member pathways
12.03 TP53 NRAS GNAQ GNA11
26 11.93 NRAS NF1 GNAQ BRAF
27 11.81 NRAS GNAQ GNA11
28 11.81 IL2 GNAQ GNA11 BRAF
29 11.81 TP53 NRAS NF1 CDKN2A BRAF
30
Show member pathways
11.78 NRAS KIT BRAF
31 11.72 KIT IL2 IFNA2
32 11.71 NRAS IL2 BRAF
33 11.69 TP53 NRAS KIT
34 11.69 NRAS IL2 GNAQ GNA11 BRAF
35 11.67 TP53 NRAS MITF
36 11.64 NRAS GNAQ GNA11
37 11.56 VEGFA TP53 CDKN2A
38 11.53 TP53 IL2 CDKN2A
39 11.49 VEGFA NRAS NF1
40 11.48 NRAS GNAQ GNA11 BRAF
41 11.42 VEGFA NRAS BRAF
42 11.22 VEGFA TP53 NRAS CDKN2A BRAF

GO Terms for Mucosal Melanoma

Biological processes related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.15 VEGFA NRAS NF1 KIT IFNA1 GNAQ
2 negative regulation of apoptotic process GO:0043066 9.91 VEGFA TP53 TERT MITF IL2 BRAF
3 positive regulation of gene expression GO:0010628 9.88 VEGFA TP53 MITF KIT CDKN2A BRAF
4 regulation of cell proliferation GO:0042127 9.86 TP53 MITF KIT BRAF
5 B cell differentiation GO:0030183 9.76 KIT IFNA2 IFNA1
6 negative regulation of protein kinase activity GO:0006469 9.67 SPRED1 NF1 GNAQ CDKN2A
7 visual learning GO:0008542 9.65 NF1 KIT BRAF
8 pigmentation GO:0043473 9.63 NF1 MITF KIT
9 Ras protein signal transduction GO:0007265 9.62 TP53 NRAS NF1 CDKN2A
10 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.6 TP53 TERT
11 developmental pigmentation GO:0048066 9.59 KIT GNA11
12 somatic stem cell division GO:0048103 9.58 KIT CDKN2A
13 phototransduction, visible light GO:0007603 9.57 GNAQ GNA11
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 VEGFA KIT IL2 IFNA2
15 entrainment of circadian clock GO:0009649 9.55 GNAQ GNA11
16 negative regulation of neuroblast proliferation GO:0007406 9.54 TP53 NF1
17 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.52 VEGFA TP53
18 myeloid progenitor cell differentiation GO:0002318 9.51 KIT BRAF
19 cytokine-mediated signaling pathway GO:0019221 9.43 VEGFA TP53 KIT IL2 IFNA2 IFNA1
20 replicative senescence GO:0090399 9.33 TP53 TERT CDKN2A
21 MAPK cascade GO:0000165 9.1 SPRED1 NRAS NF1 KIT IL2 BRAF

Molecular functions related to Mucosal Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.62 VEGFA TP53 TERT SPRED1 NRAS NF1
2 cytokine activity GO:0005125 9.56 VEGFA IL2 IFNA2 IFNA1
3 MDM2/MDM4 family protein binding GO:0097371 9.16 TP53 CDKN2A
4 type 2A serotonin receptor binding GO:0031826 8.96 GNAQ GNA11

Sources for Mucosal Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....